Texas Retina Associates

Dr. Abbey recently participated in a three-part special report video series by Ophthalmology Times that examined the evolving treatment landscape for geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD).

In it, he discusses the latest information on the two FDA-approved complement inhibitor therapies that can slow GA lesion progression: pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay).

Learn more and access all three episodes: https://www.texasretina.com/2026/06/02/dr-abbey-discusses-the-new-era-of-geographic-atrophy-management

Dr. Ashkan Abbey, who serves as Texas Retina’s Director of Clinical Research for Dallas, recently presented at the Retina World Congress 2026 meeting. He discussed the evolving clinical trial landscape for sustained drug delivery in retinal diseases like wet age-related macular degeneration (AMD) and diabetic macular edema (DME) with a focus on EYP-1901 (vorolanib intravitreal insert). The goal of sustained-release therapies like EYP-1901 is to reduce the treatment burden for patients while maintaining strong visual and anatomic outcomes.

Learn more in our latest blog article: https://www.texasretina.com/2026/05/19/dr-abbey-presented-on-retinal-sustained-drug-delivery-research-at-retina-world-congress

May is Ocular Melanoma Awareness Month. A rare but dangerous disease, ocular (uveal) melanoma often develops without symptoms and is typically first detected during a dilated eye exam.

At Texas Retina, we have been caring for ocular melanoma patients for over 40 years and are fortunate to have two physicians who sub-specialize in treating this eye cancer: Dr. Timothy Fuller and Dr. Rajiv Anand.

Learn more about ocular melanoma, including current treatment options and clinical trials available at Texas Retina: https://www.texasretina.com/2026/05/18/may-is-ocular-melanoma-awareness-month-3

Dr. Abbey recently appeared on the ReachMD podcast to discuss how retinal vein occlusion can serve as a marker of systemic risk for other conditions like hypertension, diabetes, dyslipidemia and cerebrovascular disease.

Learn more and access the podcast episode: https://www.texasretina.com/2026/05/11/dr-abbey-discusses-retinal-vein-occlusion-as-a-marker-of-systemic-risk

We love hearing feedback like this! Dr. Kothari cares for patients in our Grapevine, Arlington and Mansfield offices.

While she enjoys every aspect of practicing retina -- from clinic to surgery -- what she appreciates most is the privilege of taking care of patients. Dr. Kothari understands that many patients are fearful of losing their vision, so she always strives to provide the best possible care delivered with compassion.

You can learn more about Dr. Kothari here: https://www.texasretina.com/our-physicians/nikisha-kothari-md